FY2025 EPS Estimates for CervoMed Decreased by Analyst

CervoMed Inc. (NASDAQ:CRVO) – Investment analysts at Chardan Capital dropped their FY2025 earnings per share (EPS) estimates for shares of CervoMed in a research note issued to investors on Monday, March 24th. Chardan Capital analyst D. Gataulin now expects that the company will post earnings per share of ($2.68) for the year, down from their prior estimate of ($1.22). Chardan Capital currently has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share.

CervoMed (NASDAQ:CRVO) last announced its quarterly earnings results on Monday, March 17th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.13). CervoMed had a negative net margin of 118.68% and a negative return on equity of 44.11%. The company had revenue of $2.16 million for the quarter, compared to analyst estimates of $1.51 million.

Several other research firms also recently issued reports on CRVO. Morgan Stanley reiterated an “underweight” rating on shares of CervoMed in a report on Wednesday, December 11th. HC Wainwright lowered shares of CervoMed from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 17th. Jones Trading raised shares of CervoMed from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research note on Thursday, March 13th. D. Boral Capital restated a “buy” rating and issued a $10.00 price objective on shares of CervoMed in a report on Wednesday. Finally, Brookline Capital Management upgraded shares of CervoMed from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $27.50.

CervoMed Stock Up 11.5 %

Shares of NASDAQ CRVO opened at $9.48 on Thursday. The business’s 50 day moving average is $4.00 and its two-hundred day moving average is $7.64. CervoMed has a 52-week low of $1.80 and a 52-week high of $25.92. The firm has a market cap of $82.50 million, a price-to-earnings ratio of -4.67 and a beta of 1.84.

Institutional Trading of CervoMed

Institutional investors and hedge funds have recently modified their holdings of the business. Woodline Partners LP acquired a new stake in CervoMed during the 4th quarter valued at $175,000. Nuveen Asset Management LLC increased its position in CervoMed by 113.6% during the 4th quarter. Nuveen Asset Management LLC now owns 41,569 shares of the company’s stock worth $97,000 after purchasing an additional 22,104 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in CervoMed in the 4th quarter valued at about $32,000. Mariner LLC purchased a new position in CervoMed in the 4th quarter valued at about $30,000. Finally, DRW Securities LLC acquired a new stake in shares of CervoMed during the 4th quarter worth about $30,000. Hedge funds and other institutional investors own 25.15% of the company’s stock.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.